Navigation Links
Paratek Announces Appointments of Dennis Molnar as Chief Executive Officer and Director and of Dr. Evan Loh as Chief Medical Officer and Chairman of the Board of Directors

BOSTON, May 22, 2012 /PRNewswire/-- Paratek Pharmaceuticals, Inc. today announced that Dennis Molnar, formerly Paratek's Vice President, Corporate Development, has been appointed President, Chief Executive Officer and Director, succeeding former CEO Thomas J. Bigger, following his resignation earlier this year.  In addition, Evan Loh, MD, former senior R&D executive at Pfizer and Wyeth and who led regulatory approval for the antibiotic Tygacil®, has joined the Company as Chief Medical Officer and as Chairman of the Board of Directors.  Former Chairman, Dr. Walter Gilbert, will continue to serve on the Board as Vice Chairman.

"It has been a privilege to work with Tom Bigger and the rest of the team over the last eleven years as we have built and advanced a diversified pipeline," said Mr. Molnar.  "We are excited about the addition of Dr. Loh as Chairman and Chief Medical Officer, and we look forward to the next chapter of the Company's development with his involvement."

Dr. Loh stated, "The need for new treatments for antibiotic resistance has never been greater, and many in the clinical community see an unfolding crisis that will require continued commitments to innovation, drug development expertise and close partnerships with regulatory agencies around the globe.  I am excited to join the Paratek team and meet this challenge head on."

Paratek recently announced agreement with the U.S. Food and Drug Administration (FDA) on its second Special Protocol Assessment (SPA) related to the design of the Phase 3 program for the Company's lead antibiotic candidate, omadacycline (formerly PTK 0796).  Omadacycline is a first-in-class aminomethylcycline antibiotic with oral and IV formulations with a broad spectrum of activity designed for community-acquired bacterial infections such as acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP) and urinary tract infections (UTIs), including serious infections that are increasingly leading to hospitalization and where resistant bacteria are a growing clinical concern.  Omadacycline is being developed for first line use as empiric monotherapy in serious community-acquired infections where the Company believes its spectrum, dosing regimen and safety profile to be advantageous, without the serious safety complications, such as sudden cardiovascular death, bone marrow suppression and kidney toxicity, that accompany some other therapies. 

Additional programs at Paratek include a narrow spectrum tetracycline-derived small molecule optimized for acne and rosacea with a Phase 2 trial planned to begin later this year and preclinical programs for non-infective applications of the Company's proprietary tetracycline technology platform in spinal muscular atrophy (SMA), multiple sclerosis (MS) and rheumatoid arthritis (RA).

Mr. Molnar has 19 years of experience in the pharmaceutical and biotechnology industries, working in a variety of capacities, including business development, management, finance, and consulting.  He joined Paratek in 2001, attaining the position of Vice President, Corporate Development.  During his tenure at the Company, Paratek signed collaboration and licensing agreements with a broad range of organizations to advance Paratek's product portfolio.  Prior to joining Paratek, Mr. Molnar was President of JBI Associates, LLC, a software and consulting firm providing services to hospital pharmacies.  From 1998 to 2000, Mr. Molnar served as Director of Finance and Business Development at Magainin Pharmaceuticals.  Prior to receiving his MBA in Healthcare Management from the Wharton School of Management in 1998, Mr. Molnar held a series of positions at Bogart Delafield Ferrier, Inc., a strategic management consulting firm, providing services to the pharmaceutical and biotechnology industries.  Mr. Molnar earned a B.A. in Biology and Economics from Brown University.

Dr. Loh is former Senior Vice President, Development and Strategic Operations, Worldwide Research and Development, Pfizer.  Prior to joining Pfizer in 2009, Dr. Loh was Vice President, Clinical Research & Development at Wyeth, where he had global responsibility for scientific, strategic and operational leadership of clinical development efforts across multiple therapeutic areas.  He is the 2006 recipient of the Heroes of Chemistry Award from the American Chemical Society for his leadership role at Wyeth in the clinical development of Tygacil®, a novel glycylcycline broad-spectrum antibiotic.  Dr. Loh received his A.B. from Harvard College and his M.D. from Harvard Medical School.  He completed his Internal Medicine and Cardiovascular fellowship training at Brigham and Women's Hospital in Boston, MA.  Dr. Loh served as a faculty member at both Harvard Medical School and the University of Pennsylvania School of Medicine.  

About Paratek Pharmaceuticals
Paratek Pharmaceuticals, Inc. is engaged in the discovery and commercialization of new therapeutics that treat serious and life-threatening diseases, with a particular focus on the growing worldwide problem of antibiotic resistance.  Paratek has designed and is developing novel compounds that can circumvent or block bacterial resistance.  Paratek's lead compound, omadacycline (formerly PTK 0796), is a first-in-class aminomethylcycline antibiotic with oral and IV formulations.  Paratek has reached SPA agreements with the FDA for development of omadacycline in both ABSSSI and CABP.  Omadacycline is active against the key organisms found in important community-acquired infections such as ABSSSI, CABP and UTI, including resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus), MDR-SP (multi-drug resistant Streptococcus pneumoniae), and extended spectrum beta-lactamase (ESBL) producing Enterobacteriaceae.  As these infections have become increasingly prevalent, omadacycline is being developed by Paratek as a first-line monotherapy that may be reliably used for serious and resistant infections where hospitalization is a consideration.  Omadacycline has been tested in more than 500 healthy subjects, and oral and IV formulations of omadacycline have been compared to Zyvox ® in Phase 2 and Phase 3 clinical studies in more than 350 patients with complicated skin and skin structure infections (cSSSI). The Company believes that omadacycline has the potential to become an alternative for first-line empiric monotherapy in serious community-acquired infections such as CABP and ABSSSI that would potentially avoid the risk of sudden cardiovascular death, bone marrow suppression and kidney toxicity that accompany some other therapies. 

Paratek has an active chemical synthesis effort to produce novel and diverse small molecule tetracycline derivatives that has yielded non-antibacterial compounds with improved activity in serious inflammatory and autoimmune diseases including multiple sclerosis (MS) and rheumatoid arthritis (RA).  In addition, Paratek is developing distinct tetracycline derivatives that specifically modify mRNA splicing, with therapeutic potential in spinal muscular atrophy (SMA).

Paratek has active collaborations with Warner Chilcott and NIH to develop tetracycline-derived small molecule drugs for acne and rosacea and SMA, respectively.  Paratek is privately held and headquartered in Boston, Massachusetts, USA.  For more information, visit Paratek's website at

CONTACT: Kathryn M. Boxmeyer, Vice President & CFO, Paratek Pharmaceuticals, Inc., +1-617-275-0040 ext. 238,; Justin Jackson, Burns McClellan, Inc. for Paratek Pharmaceuticals, Inc., +1-212-213-0006,

SOURCE Paratek Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Paratek to Present Clinical Data at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy
2. Cord Blood America Announces First Quarter Financial Results
3. Sigma-Aldrich Corporation Announces New Credit Facility
4. MultiCell Technologies Announces Positive Preclinical Results for MCT-465 and MCT-485 in Primary Liver Cancer In Vitro Models
5. Novocure Announces Launch of Recurrent Glioblastoma Product Website
6. 3SBio Inc. Announces Unaudited First Quarter 2012 Results
7. Algae.Tec Announces Commencement of Australian Advanced Biofuels Facility Commissioning
8. Phalanx Biotech Group Announces CytoOneArray®, a Targeted Chromosomal Microarray
9. Sangamo BioSciences Announces Presentations At Upcoming Investor Conferences
10. Ariosa Diagnostics Announces Nationwide Launch of the Harmony™ Prenatal Test Through LabCorp
11. PDL BioPharma Announces First Quarter 2012 Financial Results
Post Your Comments:
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young Investigator ... Members of the Class of 2016 were selected from a pool of 128 ... About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... ... In a new case report published today in STEM CELLS Translational Medicine, doctors ... being treated for breast cancer benefitted from an injection of stem cells derived from ... frequent side effect of cancer treatment. , Lymphedema refers to the swelling ...
Breaking Biology Technology:
(Date:3/31/2016)... Florida , March 31, 2016 ... ) ("LegacyXChange" or the "Company") LegacyXChange ... potential users of its soon to be launched online ... ( ) will also provide potential ... use of DNA technology to an industry that is ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/21/2016)... Unique technology combines v ... security   Xura, Inc. ... digital communications services, today announced it is working alongside ... customers, particularly those in the Financial Services Sector, the ... within a mobile app, alongside, and in combination with, ...
Breaking Biology News(10 mins):